Aurantio-obtusin

CAS# 67979-25-3

Aurantio-obtusin

Catalog No. BCN1222----Order now to get a substantial discount!

Product Name & Size Price Stock
Aurantio-obtusin:5mg $53.00 In Stock
Aurantio-obtusin:10mg Please Inquire Instock
Aurantio-obtusin:20mg Please Inquire Instock
Aurantio-obtusin:50mg Please Inquire Instock

Quality Control of Aurantio-obtusin

Number of papers citing our products

Chemical structure

Aurantio-obtusin

3D structure

Chemical Properties of Aurantio-obtusin

Cas No. 67979-25-3 SDF Download SDF
PubChem ID 155011 Appearance Orange powder
Formula C17H14O7 M.Wt 330.29
Type of Compound Anthraquinones Storage Desiccate at -20°C
Solubility Soluble in chloroform, DMSO and methan
Chemical Name 1,3,7-trihydroxy-2,8-dimethoxy-6-methylanthracene-9,10-dione
SMILES CC1=C(C(=C2C(=C1)C(=O)C3=CC(=C(C(=C3C2=O)O)OC)O)OC)O
Standard InChIKey RNXZPKOEJUFJON-UHFFFAOYSA-N
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Source of Aurantio-obtusin

The seeds of Cassia obtusifolia L.

Biological Activity of Aurantio-obtusin

DescriptionAurantio-obtusin possesses anti-allergic, vasorelaxation, hypotensive and hypolipidemic effects, it is a promising osteoanabolic compound with potential therapeutic applications in the prevention of osteoporosis and other metabolic bone diseases. Aurantio-obtusin can inhibit allergic responses in IgE-mediated mast cells and anaphylactic models, it suppresses degranulation, histamine production, and reactive oxygen species generation and inhibits the production and mRNA expression of tumor necrosis factor-α and interleukin-4, and also suppresses the prostaglandin E2 production and expression of cyclooxygenase 2.
TargetsTNF-α | NO | Akt | NOS | PI3K | Serine | COX | ROS | PGE | IL Receptor
In vitro

Cassia tora Seed Extract and Its Active Compound Aurantio-obtusin Inhibit Allergic Responses in IgE-Mediated Mast Cells and Anaphylactic Models.[Pubmed: 26434611 ]

J Agric Food Chem. 2015 Oct 21;63(41):9037-46.

Cassia tora seed is widely used due to its various biological properties including anticancer, antidiabetic, and anti-inflammatory effects. However, there has been no report of the effects of C. tora seed extract (CTE) on immunoglobulin E (IgE)-mediated allergic responses.
METHODS AND RESULTS:
In this research, we demonstrated the effects of CTE and its active compound Aurantio-obtusin on IgE-sensitized allergic reactions in mast cells and passive cutaneous anaphylaxis (PCA). CTE and Aurantio-obtusin suppressed degranulation, histamine production, and reactive oxygen species generation and inhibited the production and mRNA expression of tumor necrosis factor-α and interleukin-4. CTE and Aurantio-obtusin also suppressed the prostaglandin E2 production and expression of cyclooxygenase 2. Furthermore, CTE and Aurantio-obtusin suppressed IgE-mediated FcεRI signaling such as phosphorylation of Syk, protein kinase Cμ, phospholipase Cγ, and extracellular signal-regulated kinases. CTE and Aurantio-obtusin blocked mast cell-dependent PCA in IgE-mediated mice.
CONCLUSIONS:
These results suggest that CTE and Aurantio-obtusin are a beneficial treatment for allergy-related diseases.

Aurantio-obtusin stimulates chemotactic migration and differentiation of MC3T3-E1 osteoblast cells.[Pubmed: 24841966]

Planta Med. 2014 May;80(7):544-9.

Osteoporosis is one of the major metabolic bone diseases and is among the most challenging noncommunicable diseases to treat. Although there is an increasing interest in identifying bioactive molecules for the prevention and management of osteoporosis, such studies principally focus only on differentiation and mineralization of osteoblasts or inhibition of osteoclast activity. Stimulation of osteoblast migration must be a promising osteoanabolic strategy for improved metabolic bone disease therapy.
METHODS AND RESULTS:
In this study, we show that an anthraquinone derivative, Aurantio-obtusin, stimulated chemotactic migration of MC3T3-E1 osteoblast cells in a concentration-dependent manner. The use of a real-time chemotaxis analyzing system, TAXIScan, facilitated the evaluation of both velocity and directionality of osteoblast migration in response to the compound. Besides migration, the compound stimulated osteoblast differentiation and mineralization.
CONCLUSIONS:
Taken together, the data presented in this paper demonstrate that Aurantio-obtusin is a promising osteoanabolic compound of natural origin with potential therapeutic applications in the prevention of osteoporosis and other metabolic bone diseases.

In vivo

Metabolomics-based Study of the Lipid Regulating Effect of Aurantio-obtusin on Hyperlipidemia Rats.[Reference: WebLink]

Journal of Analytical Science,2016, 32(2):178-82.

The influences of Aurantio-obtusin on endogenous metabolites in blood of hyperlipemia rats were investigated by metabonomics method in order to find the related biomarkers.
METHODS AND RESULTS:
The rat model was established by hyperlipidemia rats that were raised by high fat diet and then treated with intragastric administration of Aurantio-obtusin.Metabolites in plasma of hyperlipidemia rats were accurately analyzed by gas chromatography-mass spectrometry.In order to find out the potential biomarkers,principal component analysis,partial least squares discriminant analysis and random forest algorithm were used to study the changes of endogenous metabolite profiles in rats before modeling after modeling and after drug treatments.Ten potential biomarkers were obtained as the final achievement:alanine,glycine,valine,isoleucine,fumaric acid,serine,1,5-anhydro-D-ghlcitol,linoleic acid,stearic acid and cholesterol.
CONCLUSIONS:
This investigation demonstrates that aurantio has a good lipid regulating effect mainly by affecting the body amino acid and fatty acid metabolism.

Protocol of Aurantio-obtusin

Kinase Assay

Aurantio-obtusin relaxes systemic arteries through endothelial PI3K/AKT/eNOS-dependent signaling pathway in rats.[Pubmed: 26076958 ]

J Pharmacol Sci. 2015 Jul;128(3):108-15.

Aurantio-obtusin is a natural effective compound isolated from Semen Cassiae, which possesses hypotensive and hypolipidemic effects. Although its hypotensive effect have been clarified, mechanisms Aurantio-obtusin relaxes systemic arteries remain unclear. This study was to investigate effects and mechanisms of Aurantio-obtusin on isolated mesenteric arteries (MAs).
METHODS AND RESULTS:
We examined MAs relaxation induced by Aurantio-obtusin on rat isolated MAs, expression and activity of endothelial nitric oxide synthase (eNOS) and protein kinase B (AKT), and nitric oxide (NO) production in bovine artery endothelial cells (BAECs). Findings showed Aurantio-obtusin elicited dose-dependent vasorelaxation with phenylephrine (PE) precontracted rat MA rings (diameter: 200-300 μm), which can be diminished by denudation of endothelium and inhibition of eNOS activity, while having no effect on rat isolated pulmonary artery (PA) rings. Aurantio-obtusin increased NO production by promoting phosphorylations of eNOS at Ser-1177 and Thr-495 in endothelial cells. Aurantio-obtusin also promoted phosphorylations of Akt at Ser-473. PI3K inhibitor LY290042 could diminish vasorelaxation induced by Aurantio-obtusin. Moreover Aurantio-obtusin also elicited dose-dependent vasorelaxation effect with PE precontracted MA rings (diameter: 100-150 μm). Therefore, vasorelaxation induced by Aurantio-obtusin was dependent on endothelium integrity and NO production, which mediated by endothelial PI3K/Akt/eNOS pathway.
CONCLUSIONS:
Results suggest Aurantio-obtusin may offer therapeutic effects in hypertension, as a new potential vasodilator.

Animal Research

Biotransformation of glucoaurantio-obtusin towards aurantio-obtusin increases the toxicity of irinotecan through increased inhibition towards SN-38 glucuronidation.[Pubmed: 24842785]

Phytother Res. 2014 Oct;28(10):1577-80.

The present study aims to investigate the influence of irinotecan's toxicity by the biotransformation of glucoAurantio-obtusin to Aurantio-obtusin.
METHODS AND RESULTS:
Intraperitoneal administration (i.p.) of 100 mg/kg Aurantio-obtusin significantly increased the toxicity of irinotecan, but the i.p. administration of 100 mg/kg glucoAurantio-obtusin showed negligible influence towards irinotecan's toxicity. Furthermore, the mechanism was explained through determining the inhibition potential of glucoAurantio-obtusin and Aurantio-obtusin towards the glucuronidation metabolism of SN-38 that has been regarded to be the major active product responsible for the toxicity of irinotecan. The results showed that Aurantio-obtusin exhibited strong competitive inhibition towards the glucuronidation of SN-38, but negligible inhibition potential of glucoAurantio-obtusin towards SN-38 glucuronidation was observed.
CONCLUSIONS:
These results showed that biotransformation of glucoAurantio-obtusin towards Aurantio-obtusin increased the toxicity of irinotecan through increased inhibition of SN-38 glucuronidation.

Aurantio-obtusin Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Aurantio-obtusin Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Aurantio-obtusin

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.0276 mL 15.1382 mL 30.2764 mL 60.5528 mL 75.6911 mL
5 mM 0.6055 mL 3.0276 mL 6.0553 mL 12.1106 mL 15.1382 mL
10 mM 0.3028 mL 1.5138 mL 3.0276 mL 6.0553 mL 7.5691 mL
50 mM 0.0606 mL 0.3028 mL 0.6055 mL 1.2111 mL 1.5138 mL
100 mM 0.0303 mL 0.1514 mL 0.3028 mL 0.6055 mL 0.7569 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on Aurantio-obtusin

Cassia tora Seed Extract and Its Active Compound Aurantio-obtusin Inhibit Allergic Responses in IgE-Mediated Mast Cells and Anaphylactic Models.[Pubmed:26434611]

J Agric Food Chem. 2015 Oct 21;63(41):9037-46.

Cassia tora seed is widely used due to its various biological properties including anticancer, antidiabetic, and anti-inflammatory effects. However, there has been no report of the effects of C. tora seed extract (CTE) on immunoglobulin E (IgE)-mediated allergic responses. In this research, we demonstrated the effects of CTE and its active compound Aurantio-obtusin on IgE-sensitized allergic reactions in mast cells and passive cutaneous anaphylaxis (PCA). CTE and Aurantio-obtusin suppressed degranulation, histamine production, and reactive oxygen species generation and inhibited the production and mRNA expression of tumor necrosis factor-alpha and interleukin-4. CTE and Aurantio-obtusin also suppressed the prostaglandin E2 production and expression of cyclooxygenase 2. Furthermore, CTE and Aurantio-obtusin suppressed IgE-mediated FcepsilonRI signaling such as phosphorylation of Syk, protein kinase Cmu, phospholipase Cgamma, and extracellular signal-regulated kinases. CTE and Aurantio-obtusin blocked mast cell-dependent PCA in IgE-mediated mice. These results suggest that CTE and Aurantio-obtusin are a beneficial treatment for allergy-related diseases.

Biotransformation of glucoaurantio-obtusin towards aurantio-obtusin increases the toxicity of irinotecan through increased inhibition towards SN-38 glucuronidation.[Pubmed:24842785]

Phytother Res. 2014 Oct;28(10):1577-80.

The present study aims to investigate the influence of irinotecan's toxicity by the biotransformation of glucoAurantio-obtusin to Aurantio-obtusin. Intraperitoneal administration (i.p.) of 100 mg/kg Aurantio-obtusin significantly increased the toxicity of irinotecan, but the i.p. administration of 100 mg/kg glucoAurantio-obtusin showed negligible influence towards irinotecan's toxicity. Furthermore, the mechanism was explained through determining the inhibition potential of glucoAurantio-obtusin and Aurantio-obtusin towards the glucuronidation metabolism of SN-38 that has been regarded to be the major active product responsible for the toxicity of irinotecan. The results showed that Aurantio-obtusin exhibited strong competitive inhibition towards the glucuronidation of SN-38, but negligible inhibition potential of glucoAurantio-obtusin towards SN-38 glucuronidation was observed. These results showed that biotransformation of glucoAurantio-obtusin towards Aurantio-obtusin increased the toxicity of irinotecan through increased inhibition of SN-38 glucuronidation.

Aurantio-obtusin stimulates chemotactic migration and differentiation of MC3T3-E1 osteoblast cells.[Pubmed:24841966]

Planta Med. 2014 May;80(7):544-9.

Osteoporosis is one of the major metabolic bone diseases and is among the most challenging noncommunicable diseases to treat. Although there is an increasing interest in identifying bioactive molecules for the prevention and management of osteoporosis, such studies principally focus only on differentiation and mineralization of osteoblasts or inhibition of osteoclast activity. Stimulation of osteoblast migration must be a promising osteoanabolic strategy for improved metabolic bone disease therapy. In this study, we show that an anthraquinone derivative, Aurantio-obtusin, stimulated chemotactic migration of MC3T3-E1 osteoblast cells in a concentration-dependent manner. The use of a real-time chemotaxis analyzing system, TAXIScan, facilitated the evaluation of both velocity and directionality of osteoblast migration in response to the compound. Besides migration, the compound stimulated osteoblast differentiation and mineralization. Taken together, the data presented in this paper demonstrate that Aurantio-obtusin is a promising osteoanabolic compound of natural origin with potential therapeutic applications in the prevention of osteoporosis and other metabolic bone diseases.

Aurantio-obtusin relaxes systemic arteries through endothelial PI3K/AKT/eNOS-dependent signaling pathway in rats.[Pubmed:26076958]

J Pharmacol Sci. 2015 Jul;128(3):108-15.

Aurantio-obtusin is a natural effective compound isolated from Semen Cassiae, which possesses hypotensive and hypolipidemic effects. Although its hypotensive effect have been clarified, mechanisms Aurantio-obtusin relaxes systemic arteries remain unclear. This study was to investigate effects and mechanisms of Aurantio-obtusin on isolated mesenteric arteries (MAs). We examined MAs relaxation induced by Aurantio-obtusin on rat isolated MAs, expression and activity of endothelial nitric oxide synthase (eNOS) and protein kinase B (AKT), and nitric oxide (NO) production in bovine artery endothelial cells (BAECs). Findings showed Aurantio-obtusin elicited dose-dependent vasorelaxation with phenylephrine (PE) precontracted rat MA rings (diameter: 200-300 mum), which can be diminished by denudation of endothelium and inhibition of eNOS activity, while having no effect on rat isolated pulmonary artery (PA) rings. Aurantio-obtusin increased NO production by promoting phosphorylations of eNOS at Ser-1177 and Thr-495 in endothelial cells. Aurantio-obtusin also promoted phosphorylations of Akt at Ser-473. PI3K inhibitor LY290042 could diminish vasorelaxation induced by Aurantio-obtusin. Moreover Aurantio-obtusin also elicited dose-dependent vasorelaxation effect with PE precontracted MA rings (diameter: 100-150 mum). Therefore, vasorelaxation induced by Aurantio-obtusin was dependent on endothelium integrity and NO production, which mediated by endothelial PI3K/Akt/eNOS pathway. Results suggest Aurantio-obtusin may offer therapeutic effects in hypertension, as a new potential vasodilator.

Description

Aurantio-obtusin is an anthraquinone isolated from Semen Cassiae, with anti-Inflammatory, anti-oxidative, anti-coagulating and anti-hypertension activities. Aurantio-obtusin relaxes systemic arteries through endothelial PI3K/AKT/eNOS-dependent signaling pathway in rats, thus acts as a new potential vasodilator. Aurantio-obtusin inhibits allergic responses in IgE-mediated mast cells and anaphylactic models and is potential for treatment for allergy-related diseases.

Keywords:

Aurantio-obtusin,67979-25-3,Natural Products, buy Aurantio-obtusin , Aurantio-obtusin supplier , purchase Aurantio-obtusin , Aurantio-obtusin cost , Aurantio-obtusin manufacturer , order Aurantio-obtusin , high purity Aurantio-obtusin

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: